Enanta Pharmaceuticals | ENTA - Current Liabilities


Enanta Pharmaceuticals reported $44.73M in Current Liabilities for its fiscal quarter ending in December of 2025.





Current Liabilities Change Date
AbbVie USD 43.29B 3.9B Dec/2025
Amgen USD 24.96B 534M Mar/2026
Anika Therapeutics USD 20.97M 942K Mar/2026
Arrowhead Research USD 347.42M 151.94M Dec/2025
AstraZeneca USD 32.57B 1.95B Mar/2026
BioCryst Pharmaceuticals USD 196.07M 5.83M Dec/2025
Biogen USD 3B 350.5M Mar/2026
Bristol-Myers Squibb USD 19.16B 4.26B Mar/2026
Enanta Pharmaceuticals USD 44.73M 3.83M Dec/2025
Gilead Sciences USD 11.81B 485M Dec/2025
GlaxoSmithKline GBP 22.43B 1.04B Mar/2026
Halozyme Therapeutics USD 177.09M 660.14M Dec/2025
Heron Therapeutics USD 96.1M 6.39M Dec/2025
Immunic USD 30.62M 539K Dec/2025
Incyte USD 1.49B 25.52M Mar/2026
Insmed USD 468.87M 51.66M Dec/2025
Ionis Pharmaceuticals USD 717M 66M Mar/2026
J&J USD 57.72B 3.59B Mar/2026
Karyopharm Therapeutics USD 92.06M 4.9M Dec/2025
Ligand Pharmaceuticals USD 37.45M 6.91M Dec/2025
Merck USD 26.94B 1.38B Mar/2026
Neurocrine Biosciences USD 831.7M 88.3M Mar/2026
Novartis USD 31.37B 4.1B Mar/2026
Novavax USD 459.95M 30.08M Dec/2025
Pfizer USD 34.35B 2.64B Mar/2026
PTC Therapeutics USD 968.43M 102.18M Dec/2025
Roche Holding CHF 28B 421M Dec/2025
Sarepta Therapeutics USD 1.1B 173.86M Dec/2025
Vertex Pharmaceuticals USD 3.88B 19.4M Mar/2026